The correction is positive for existing shareholders, the option exchange overhang is 76% smaller than originally feared. However, the proposal still transfers value from shareholders to option holders by repricing underwater options. Monitor the June 16 vote outcome; if approved, the exchange will occur immediately. The stock's $4.09 close suggests the market has already priced in significant dilution risk, this correction may provide a modest relief rally.
AGEN drugs
AGEN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $3.47entry
- T+1 · 6mo ago +3.17%α +2.39% · $3.58
- T+5 · 6mo ago −9.22%α −9.08% · $3.15
- T+20 · 5mo ago −2.31%α −1.69% · $3.39
- T+60 · 3mo ago +100.58%α +96.14% · $6.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Agenus filed a DEFA14A supplement correcting a material error in its April 30 proxy statement: the number of options eligible for the proposed one-time exchange was overstated by 4x (8,697,165 originally stated, corrected to 2,103,891). The exchange would replace deeply underwater options (weighted-average exercise price $46.27 vs. $4.09 closing price) with new options at fair market value for most employees and at a 150% premium for executives/directors. The correction reduces the perceived dilution and overhang from the proposal, but the underlying retention rationale and vote mechanics are unchanged.
Key Financial Metrics
Key Facts
- Corrected eligible option count from 8,697,165 to 2,103,891, a 76% reduction
- Eligible options have weighted-average exercise price of $46.27 vs. $4.09 closing price (100% underwater)
- CEO Garo Armen holds 838,377 of 2,103,891 total eligible options (39.9%)
- Proposal 4 is a one-for-one option exchange with 150% premium strike for Tier 1 (executives/directors) and 100% FMV for Tier 2
- Special meeting scheduled for June 16, 2026; majority of votes cast required for approval
- Broker non-votes and abstentions have no effect on Proposal 4 outcome
Financial Impact
No direct dollar impact. The correction reduces potential accounting compensation cost from the exchange by ~76% vs. the erroneously stated figure. Incremental compensation cost measured as excess of new option fair value over surrendered option fair value.
Risk Factors
- Option exchange still dilutes existing shareholders if stock appreciates above new strike prices
- CEO holds ~40% of eligible options, concentrated insider benefit from repricing
- No guarantee of FDA accelerated approval for BOT+BAL in 2026, binary regulatory risk remains
- Company reduced net burn from >$200M to ~$50M but still cash-flow negative
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-221408 |
| Document: 0001193125-26-221408-index-headers.html | 0001193125-26-221408 |
| Document: 0001193125-26-221408-index.html | 0001193125-26-221408 |
| Document: 0001193125-26-221408.txt | 0001193125-26-221408 |
Track record
12 reports on AGEN
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Viewing Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers